Clarus closes $660m bio fund
This article was originally published in Clinica
Executive Summary
Clarus Ventures has raised $660m for its second life sciences investment fund, Clarus II. The money will be invested over three years in medical technology, biotechnology and specialty pharmaceutical companies. Clarus said between $20-60m will be allocated to each portfolio company. The VC raised $500m in its first investment fund in late 2005 - to date, around 90% of the proceeds have been committed. Clarus Ventures has offices on the US east and west coast.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.